表紙：呼吸器治療薬の市場規模、シェア、成長分析、薬剤クラス別、疾患タイプ別、投与経路別、流通チャネル別、地域別、2025～2032年産業予測

市場調査レポート

商品コード

1755445

呼吸器治療薬の市場規模、シェア、成長分析、薬剤クラス別、疾患タイプ別、投与経路別、流通チャネル別、地域別、2025～2032年産業予測

Respiratory Drugs Market Size, Share, and Growth Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists ), By Disease Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年06月16日
発行: SkyQuest
ページ情報: 英文 197 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 771,574円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 902,596円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,033,618円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.58円

全表示
概要
目次

概要

サンプル依頼リストに入れる

呼吸器治療薬の世界市場規模は2023年に37億米ドルと評価され、2024年の40億1,000万米ドルから2032年には77億1,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは8.5%で成長する展望です。

呼吸器治療薬市場は、世界の呼吸器疾患の急増を背景に、2025～2032年にかけて大きく成長する展望です。大気汚染の増加、アレルゲン曝露の増加、呼吸器疾患に対する意識の高まりなどの治療要因により、診断率や治療率が高まっています。高所得国では、慢性閉塞性肺疾患（COPD）の70％以上がタバコの喫煙に起因しているが、中低所得国では30～40％で、家庭の大気汚染も重要な役割を果たしています。喫煙は肺機能に長期的なダメージを与えるため、COPD、肺がん、呼吸器感染症などの呼吸器疾患の主要な原因であることに変わりはないです。このことは、これらの一般的な症状を管理するための効果的な呼吸器治療薬が緊急に必要であることを強調しています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主要市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）
  主要企業プロファイル
  - GlaxoSmithKline Plc（GSK）（英国）
  - AstraZeneca Plc（英国）
  - Boehringer Ingelheim International GmbH（ドイツ）
  - Merck & Co., Inc.（米国）
  - Novartis AG（スイス）
  - F. Hoffmann-La Roche Ltd.（スイス）
  - Teva Pharmaceutical Industries Ltd.（イスラエル）
  - Sanofi（フランス）
  - Pfizer Inc.（米国）
  - AbbVie Inc.（米国）
  - Vertex Pharmaceuticals Incorporated（米国）
  - Mylan Pharmaceuticals Inc.（米国）
  - Sun Pharmaceutical Industries Ltd.（インド）
  - Lupin Limited（インド）
  - Cipla Limited（インド）
  - Chiesi Farmaceutici S.p.A.（イタリア）
  - Sumitomo Dainippon Pharma Co., Ltd.（日本）
  - Beximco Pharmaceuticals Ltd.（バングラデシュ）
  - Respirerx Pharmaceuticals Inc.（米国）
  - Viatris Inc.（米国）

結論と提言

Product Code: SQMIG35I2377

Global Respiratory Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.01 billion in 2024 to USD 7.71 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The respiratory drugs market is poised for significant growth between 2025 and 2032, driven by a surge in respiratory disorders globally. Factors such as rising air pollution, increased allergen exposure, and heightened awareness of respiratory diseases have led to greater diagnosis and treatment rates. In high-income countries, over 70% of Chronic Obstructive Pulmonary Disease (COPD) cases are attributed to tobacco smoking, while in low- and middle-income countries, this figure is 30-40%, with household air pollution also playing a critical role. Smoking remains a leading cause of respiratory issues, including COPD, lung cancer, and respiratory infections, as it inflicts long-term damage on lung function. This underscores the urgent need for effective respiratory therapies to manage these prevalent conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Respiratory Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Respiratory Drugs Market Segments Analysis

Global Respiratory Drugs Market is segmented by Drug Class, Disease Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs and Others. Based on Disease Type, the market is segmented into Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion and Others. Based on Route of Administration, the market is segmented into Inhalation, Enteral and Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is significantly driven by advancements in artificial intelligence, which are transforming the discovery process of new respiratory medications. By swiftly analyzing extensive datasets, AI technologies can pinpoint potential compounds and biological targets with remarkable speed and efficiency. Machine learning algorithms can effectively simulate the interactions between drug candidates and human biology, thereby streamlining the preclinical phase and accelerating overall development timelines. Notably, AI platforms such as BenevolentAI and Atomwise are being harnessed to create groundbreaking therapies for conditions like asthma and chronic obstructive pulmonary disease (COPD), empowering pharmaceutical companies to enhance innovation while minimizing research and development costs.

Restraints in the Global Respiratory Drugs Market

The Global Respiratory Drugs market faces certain constraints, particularly in the integration of artificial intelligence into drug development. This process demands a significant investment in computational infrastructure, skilled workforce, and ongoing software enhancements, which can be financially burdensome for smaller pharmaceutical firms or those operating in developing regions. Additionally, the challenge of incorporating AI tools into existing legacy systems often results in technical and logistical difficulties, hindering the progress of digital transformation within research and development efforts for respiratory medications. These factors collectively pose considerable obstacles to the advancement and efficiency of respiratory drug innovation in the market.

Market Trends of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is increasingly influenced by the rise of AI-enabled smart inhalers, which are transforming respiratory care. These innovative devices, such as Propeller Health's inhaler sensors, track medication adherence, monitor symptoms, and offer real-time feedback to both patients and healthcare providers. By ensuring proper inhaler techniques and minimizing missed doses, these technologies enhance patient engagement and adherence to treatment protocols. Furthermore, the data generated facilitates personalized treatment plans, thereby improving clinical outcomes. As advancements in AI and digital health technology progress, the integration of smart inhalers is expected to drive substantial growth in the respiratory drugs sector, meeting the rising demand for more effective, personalized healthcare solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Respiratory Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Short-Acting Beta2-Agonists (SABA)
Long-Acting Beta2-Agonists (LABA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Antihistamines
Vasodilators
Combination Drugs
Others

Global Respiratory Drugs Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Pleural Effusion
Others

Global Respiratory Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Inhalation
Enteral
Parenteral

Global Respiratory Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Respiratory Drugs Market Size & CAGR (2025-2032)

North America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

GlaxoSmithKline Plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi Farmaceutici S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beximco Pharmaceuticals Ltd. (Bangladesh)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Respirerx Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

呼吸器治療薬の市場規模、シェア、成長分析、薬剤クラス別、疾患タイプ別、投与経路別、流通チャネル別、地域別、2025～2032年産業予測

Respiratory Drugs Market Size, Share, and Growth Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists ), By Disease Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主要市場の考察

呼吸器治療薬市場規模：薬剤クラス別&CAGR（2025～2032年）

呼吸器治療薬市場規模：疾患タイプ別&CAGR（2025～2032年）

呼吸器治療薬市場規模：投与経路別&CAGR（2025～2032年）

呼吸器治療薬市場規模：流通チャネル別&CAGR（2025～2032年）

呼吸器治療薬市場規模&CAGR（2025～2032年）